Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GDUFA II: Inspection Information Takes Center Stage

This article was originally published in The Pink Sheet Daily

Executive Summary

Sponsors say transparency is important as generic drug user fee negotiations move to inspection policy.

You may also be interested in...



US FDA's Inspection Decisions To Be Swayed By Facility "History" With Foreign Regulators

Leveraging foreign surveillance inspections could help FDA ensure more sites are inspected more often.

FDA Will Soon Begin Alerting Generics Firms To Facility Compliance Status

US FDA's GDUFA II commitment to alert generics firms within 90 days regarding inspection results will put additional pressure on Form 483 responses, possibly starting later this year.

FDA Inspections Ombudsman Could Help Foreign Manufacturers

New ORA position intended to help get questions answered, but already being used to smooth inspection issues.

Related Content

Topics

UsernamePublicRestriction

Register

PS078106

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel